[Preliminary experience with radioimmuno-guided surgery of primary XXXX of the lung].

@entity1 @entity5 @entity2 @entity1149 @entity1544 @entity1104 @entity2797
BACKGROUND: Radioimmunoguided surgery ( @entity1104 ) can be a valid option in the management of @entity2 as well as @entity5 in other anatomic sites. METHODS: We evaluated the usefulness of @entity1104 ( @entity1104 ) in the staging of primitive @entity1149 . Intraoperatively, this technique can define the lymph nodes involvement and thus, the radicality of the resection. In the first stage of our study, we looked for the epitope @entity2797 in 45 @entity1 with primary @entity1149 . The epitope was found by immunochemistry in only 6 cases. The only one operable @entity1 was injected with monoclonal antibody B 72.3, that was 125I-labelled. RESULTS: At the operation, the monoclonal antibody showed no selectivity for neoplastic cells. Neoplastic tissue and healthy tissue showed a similar detection of the monoclonal antibody both intraoperatively and at the histochemical study. Because of the problems related with this method--e.g. technical difficulties, excessive wasting of time and lack of imaging--we modified our strategy. In this second stage of our study we used fragments of murine anti-CEA monoclonal antibody F023C5. The protocol was performed in 11 @entity1 with @entity1544 . In one @entity1 operated on for an excavated @entity5 (not well-defined at the immunoscintigraphy) intraoperative detection was negative while the ex vivo counts were significant: the neoplastic tissue showed a radioactivity twice higher than healthy tissue. Furthermore, the @entity1104 found a small intraparenchimal lymph node that was seen neither by CT nor by immunoscintigraphy. CONCLUSIONS: Our data are still preliminary, but with improvement of the technique and the use of more specific monoclonal antibodies the @entity1104 could become a helpful method, able to improve the radicality of surgery for @entity2 .
